

By Speed Post/ Special Messenger

F. No. 19(719)/2016/DP/NPPA/Div.II

भारत सरकार

Government of India

रसायन और उर्वरक मंत्रालय

Ministry of Chemicals & Fertilizers

औषध विभाग

Department of Pharmaceuticals

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

National Pharmaceutical Pricing Authority


तीसरी/पांचवी मंजिल 5th / 3rd Floor,
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग
YMCA Cultural Center Building,
1, जय सिंह रोड, नई दिल्ली-110001
1, Jai Singh Road, N. Delhi - 110001.
दिनांक :- 03.04.2017

OFFICE MEMORANDUM

Subject: 4th meeting of the Committee of Experts under Para 11(3&4) of DPCO 2013

The Fifth meeting of the committee of Experts constituted under para 11(3 & 4) of DPCO, 2013 is scheduled to be held on **19.04.2017 (Wednesday) at 11.00 AM** in the conference room of National Pharmaceuticals Pricing Authority (NPPA), 3rd Floor, YMCA Cultural Center Building, 1, Jai Singh Road, New Delhi - 110001 to consider 10 cases as on date (Annexure) under the provision contained in Para 11 (3 & 4), which states that:

- (a) Notwithstanding anything contained in sub-paragraphs (1) and (2), in case of injections or inhalation or any other medicine for which dosage form or strength or both are not specified in the Schedule-I of the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specific therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopoeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation.
 - (b) The Government shall form a Committee of Experts, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the above parameters.
2. Moreover, any other issue(s) relating to above mention subject, with the permission of Chair will also be taken up/discussed in the meeting.
 3. You are, therefore, requested to make it convenient to attend the meeting.


(ए. के. खुराना)
निदेशक

Encl: As above.

To,

The Members of the Committee:-

1. Prof. Y. K. Gupta, Head, Department of Pharmacology, AIIMS, New Delhi ✓
2. Prof. V.K. Behal, Head of Department of Cardiology, AIIMS, New Delhi or representative
3. Dr. Naval K Vikram, Prof., Department of Medicine, AIIMS, New Delhi or representative
4. Prof. Rakesh Yadav, Department of Cardiology, AIIMS, New Delhi or representative
5. Prof. Balram Bhargava, Department of Cardiology, AIIMS, New Delhi or representative
6. Sh. Chandrasheka Ranga, Dy. DC (I), O/o Drug Controller General of India, Ministry of Health and Family Welfare, New Delhi ✓

7. Shri P.K. Abdul Kareem, Add. Economic Adviser, O/o Department of Economic Affairs, Economic Division, North Block, New Delhi
8. Shri D. P. Pathak, Director, Delhi Institute of Pharmaceutical Science and Research (DIPSAR)
9. Dr. Sarita Dhawan, Add. Director /Director, CGHS, New Delhi or representative
10. The Executive Director, National Health System Resource Centre or representative
11. Sh. Vijay Kumar, Scientist 'G', Indian Council of Medical Research or representative
12. Sh. Rakesh Pandey, Dy. Director, O/o CAC, Deptt of Expenditure, MoF or representative

Copy to:

1. PPS to Chairman, NPPA
2. PPS to MS, NPPA
3. PPS to Adviser (cost), NPPA

Representation of companies under para 11(3)

As on 03.04.2017

| Sr. No. | Company Name | Formulation | S.O No. | Dated | Received on | Remarks |
|---------|------------------------------------|---|---------|------------|------------------------------|---------|
| 1 | Fresenius Kabi | Paclitaxel 30mg/5ml | 644(E) | 02.03.2016 | 23.5.2016 | |
| | | Paclitaxel 30mg/1ml | 1560(E) | 27.04.2013 | | |
| 2 | Cipla | Budesonide Inhalation 100mcg & 200mcg | 1561(E) | 27.4.2016 | 12.7.2016 & 25.11.2016 | |
| 3 | Glenmark | Digihaler FB 100/200/400 and Budesonide/ Formoterol (100/6, 200/6 and 400/6mcg) | | | 15.12.2016 | |
| 4 | Envision Scientific | Albuminus DES+- An Abluminla coated Sirolimus Eluting Coronary stent System (Nostrum, Mitgator) | 4100(E) | 21.12.2016 | 07.03.2017 | |
| 5 | M/s Boston Scientific India Ltd | Synerty Evrolimus Eluting Platium Chromium Coronary Stent with Bio- Absorbable Polymer Systems | 4100(E) | 21.12.2016 | 06.03.2017 | |
| | | Promus Premeir Everolimus- Eluting Coronary Stent System | 4100(E) | 21.12.2016 | | |
| 6 | | DPT vaccine | | | | |
| 7 | | DPT + Hib + Hep B vaccine | | | | |
| 8 | | Hepatitis B Vaccine | | | | |
| 9 | M/s Ipca Laboratories | Ondansetron 2mg/ml injectables | 1951(E) | 02.6.2016 | | |
| 10 | M/s Sanofi Limited | Pheniramine Injection 22.75 mg/ml | 3431(E) | 10.11.2016 | | |